UPPSALA, Sweden, Oct. 24, 2005 (PRIMEZONE) -- Q-Med AB: Invitation to Q3 report conference call:
Time: Thursday, October 27, 2005 at 11.00 a.m. CET. To join the conference: Swedish dial in number: +46 (0) 8 505 201 10 Danish dial in number: +45 3271 4607 UK dial in number: +44 (0)2071 620 025 Password: Q-Med AB Q-Med participants: Bengt Agerup, CEO Erika Kjellberg Eriksson, CFO Anne Rhenman, Director Investor Relations and Corporate Communications
The press release for Q-Med AB's Q3 report will be issued around 08.30 CET October 27.
The slide presentation will be available at
www.q-med.com/Investors/Presentations
A recorded version of the presentation will be available for five working days on tel: Sweden +46 (0)8 505 203 33, access code: 67 82 61 or UK +44 (0)20 7031 4064, access code: 67 82 61.
Queries should be addressed to:
Anne Rhenman, Director Investor Relations and Corporate Communications, Tel: + 46 (0) 70-974 90 15
NASHA, DUROLANE, ZUIDEX, IMPLACER, DEFLUX and all the products within the RESTYLANE family are trademarks that belong to Q-Med.
In the U.S., Q-Med AB's affiliate is the wholly owned subsidiary Q-Med Scandinavia, Inc.
Q-Med AB (publ)
Seminariegatan 21, SE-752 28 Uppsala, Sweden Corporate identity number 556258-6882 Tel: +46(0) 18-474 90 00 Fax: +46(0) 18-474 90 01 info@q-med.com www.q-med.com
Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces and markets medical implants. All products are based on the company's patented NASHA technology - Non-Animal Stabilized Hyaluronic Acid. The products covered by the RESTYLANE trademark are used for the filling out of lips and facial wrinkles and for facial contouring and today account for the majority of sales. RESTYLANE is sold in over 70 countries and has been approved in the USA. DUROLANE, Q-Med's product for the treatment of osteoarthritis of the hip and knee joints, has been approved in Europe since May 2001. DEFLUX is a product which has been approved in Europe and the USA for the treatment of vesicoureteral reflux (a malformation of the urinary bladder) in children. ZUIDEX for the treatment of stress urinary incontinence in women has been sold in Europe since July 2002. Q-Med today has approximately 550 employees, with approximately 350 at the company's production facility and head office in Uppsala. The Q-Med share is listed on the O-list, Attract 40, of Stockholmsborsen.
This information was brought to you by Waymaker.
The following files are available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=143806&fn=wkr0010.pdf
-0-